 What's already known about this topic? Cell-free DNA testing in the maternal blood is a highly efficient method of screening for common fetal trisomies.
 What's already known about this topic? Cell-free DNA testing in the maternal blood is a highly efficient method of screening for common fetal trisomies.
 What does this study add? In high-risk patients after first-trimester combined screening, a policy of selecting a subgroup for invasive testing and another for cfDNA testing ensures that most trisomies are detected and allows to diagnose more than 60% of abnormalities that are not currently investigated by the cfDNA test.
Introduction
One of the most widely used methods of screening for trisomy 21, 18 and 13 is based on the combination of maternal age, sonographic measurement of fetal nuchal translucency (NT) thickness and maternal serum free ß-hCG and PAPP-A at [11] [12] [13] weeks' gestation. It has been demonstrated that the combined test can identify about 90% of fetuses with trisomy 21 and approximately 95% of those with trisomy 18 and 13, for an overall invasive testing rate of 3-5% 1 .
Recent studies have shown that cell-free DNA (cfDNA) testing in the maternal blood can detect more than 99% of fetuses with trisomy 21, 96% of trisomy 18, 92% of trisomy 13 and 90% of monosomy X, for an overall false positive rate of about 0.5% 2, 3 . In the screen positive group of combined testing, the use of cfDNA analysis has the main objectives of firstly, retain the ability to diagnose the vast majority of the chromosomal defects included in this population and secondly, substantially reduce the overall invasive testing rate of first trimester combined screening by re-assessing the risk for common trisomies in pregnancies with a screen positive result. In this respect, the components of combined testing, such as the risk score and NT thickness, should be taken into account to identify those patients that should be offered a diagnostic invasive procedure independently from the results of the cfDNA test. In addition, first trimester combined screening incidentally detects chromosomal abnormalities which are different from those targeted by the test and that cannot currently be identified by cfDNA analysis 4 .
The objective of this study was to examine the impact of cfDNA testing on the diagnosis of chromosomal defects in pregnancies with a screen positive result from the combined test and to assess the clinical value of using the combined risk score and the measurement of NT thickness to select a subgroup that should be offered invasive testing and another that could have the cfDNA test.
Methods
This was a multicentre study involving four fetal medicine centres in Italy (Mangiagalli In the laboratory, cfDNA was amplified using a massively multiplexed PCR methodology targeting 20,000 SNPs, sequenced, and analyzed with Bayesian-based algorithm to determine fetal ploidy status, as previously described 5 . The algorithm analyses a number of quality control metrics to identify laboratory or sequencing failure, estimate the amount of total starting DNA, determine the fetal fraction, and calculate the extent to which the measured cfDNA data fit expected case-specific distributions. In this study, a determination of the ploidy state of the fetus was not made if the fetal fraction was <4.0%, if the amount of input DNA was below 1500 genome equivalents, or if off-allele contamination was >0.2%. Maternal genotypic information was incorporated into the analysis as previously described 6 . Results were provided in the form of the probability for a copy number of the five chromosomes 
Statistical analysis
The data were explored and analysed using the statistical software SPSS 12.0 (Chicago, IL, USA) and Excel for Windows 2000 (Microsoft Corp., Redmond, WA, USA). Fisher's exact test was used to assess the differences in frequency distribution of categorical variables.
Results
The median maternal age of the study population was 36 (range 20-46) years, median fetal crown-rump length was 63.0 (range 45-84) mm and median NT thickness was 2.7 (range 1.0-12.7) mm. Invasive testing demonstrated chromosomal abnormalities in 71 (27.4%) of the 259 cases ( Table 1 ). The abnormalities included 8 (11.3%) that were not targeted by cfDNA testing and these are described in detail in Table 2 . Microarray-CGH analysis was carried out in 32 cases and it was abnormal in 3 fetuses (Table 2) .
On the total of 259 examined pregnancies, the cfDNA test provided a result in 249 (96.1%) cases and, among these, correctly identified as being at high risk 35 of 36 cases of trisomy 21, 13 of 13 with trisomy 18, 5 of 5 with trisomy 13 and 3 of 4 with sex chromosome aneuploidies ( Table 1 ). The test also correctly identified as being low-risk all 184 euploid cases. In 10 cases the cfDNA test did not provide results because the fetal fraction was <4% in 8 and the sample failed internal quality control in 2. The no result rate was significantly higher in the group of aneuploidies, mosaicisms and structural re-arrangements compared to chromosomally normal fetuses (8.5% vs 2.1%, p<0.05). The no result group included 1 case of trisomy 21, 2 of trisomy 18, 1 of trisomy 13, 1 of 47 XXX and 1 case with duplication in chromosome 8 ( Table 1 ).
The frequency distribution of different fetal karyotypes according to various cut-off values of combined test risk and NT thickness is shown in Figure 1 . The group of fetuses with a risk > 1 in 10 and / or NT > 4 mm included the majority of the cases with common trisomies and sex aneuploidies, more than 50% of fetuses with other defects and less than 20% of euploid pregnancies (Table 3) .
We examined the performance of a policy in which women with a risk from the combined test of >1 in 250 are subdivided into group A containing those with a risk of >1 in 10 or NT >4 mm and group B containing the remainder of cases (Figure 2) 
Discussion
This study shows that in patients identified by the first-trimester combined test as being at high-risk of trisomies, a policy of selecting a subgroup for invasive testing and another for cfDNA testing can substantially reduce the number of invasive procedures, retain the ability to diagnose most trisomies and also diagnose more than 60% of abnormalities that are not currently detectable by the cfDNA test.
Our data confirm previous evidence that sequencing of the SNP regions of cfDNA in the maternal blood is a highly efficient method of screening for common fetal trisomies [5] [6] [7] . Among cases with a result, a high risk score was provided in the vast majority of fetuses with trisomy 21, 18, 13 and monosomy X and all euploid fetuses were correctly classified as being at low risk. There were two false negative results, one each of trisomy 21 and monosomy X. In the case of trisomy 21 the fetal fraction was 4.4% and a recent study suggested, through statistical modelling, that the performance of cfDNA testing may be affected by the relative percentage of fetal DNA in the maternal circulation, with a significantly lower detection rate for trisomy 21 when the fetal fraction is below 6% 8 . Although this finding could partially explain our false negative result, further clinical studies are required to assess the relationship between the fetal fraction and the performance of cfDNA testing. The false negative case of monosomy X could be explained by the presence of a feto-placental mosaicism with an under-represented monosomic cell line in the cytotrophoblast, which is the source of cfDNA. The frequent occurrence of feto-placental mosaicism in cases with monosomy X could also explain the lower reported detection rate of cfDNA testing for this abnormality compared to the detection rate for trisomy 21 2 .
Analysis of cfDNA in the maternal blood did not provide a result in about 4% of the samples and this was mostly due to a low fetal fraction. A previous study showed that a repeated maternal blood sample would produce a result in about 60% of these cases 9 . However, our data confirm emerging evidence that the no result rate may be higher in fetuses with aneuploidies compared to those with normal karyotype 3, 7 .
Therefore, the importance of a low fetal fraction in re-assessing the risk for common trisomies after combined testing should be evaluated in large prospective clinical studies.
It has been previously reported that the screen positive group of combined testing includes cases with abnormalities which were not initially targeted and that are incidentally detected, such as other trisomies, sex aneuploidies, deletions, duplications, mosaicisms and others 4 , and these defects accounted for about 10% of all aneuploidies in our study. Two recent studies analysed data on microarray-CGH results in a large number of pregnancies undergoing prenatal invasive testing for a variety of reasons, such as maternal age > 35 years, high risk from combined testing or second trimester serum screening, maternal request and others 10, 11 . In the group of pregnancies with a high risk from aneuploidy screening, the authors reported an overall incidence of copy number variations with known clinical significance or potential clinical significance of about 1%, which is similar to what was observed in our population (Table 2 ). However, we cannot exclude that some sub-chromosomal defects may have been missed because we performed microarray-CGH analysis only in 12% of cases in our cohort. There is some evidence that cfDNA testing can identify a proportion of fetuses with sub-chromosomal abnormalities 12 . However, there are insufficient data on reliable estimates of the detection rate and false positive rate of cfDNA testing for each of these defects in the general obstetric population.
Therefore, in order to reduce the overall invasive testing rate of combined screening by using cfDNA analysis, it is inevitable that a proportion of abnormalities different from trisomy 21, 18 and 13 will not be diagnosed.
In this study, the incidence of aneuploidies in fetuses with a combined risk > 1 in 10
and NT > 4 mm was very high and a recent large study reported that this population includes only about 0.7% of the total of euploid fetuses 4 . Therefore, a policy of offering direct access to a diagnostic procedure in these cases would have a small impact on the overall invasive testing rate. In addition, it is well established that fetuses with high NT and a normal karyotype should undergo additional genetic testing that require chorionic villi or amniotic fluid samples [13] [14] .
The prevalence of common trisomies in our cohort was higher than what would have been expected in the screen-positive group of combined testing on the general obstetric population 15 and this may be due to the fact that a minority of patients were referred from other centres, with a trend towards referral of very high-risk cases. Our results are unlikely to change significantly if a contingent strategy is applied to a screen-positive population with a relatively lower proportion of cases with common trisomies and a higher number of non-trisomic fetuses, but larger clinical studies would be required to confirm our findings.
Pregnancies with a risk from the combined test of < 1 in 250 were not examined as per our study design. It has been shown that this group includes about 10% of fetuses with trisomy 21 and a proportion of euploid fetuses which increases with decreasing combined risk cut-offs 15 . A recent study showed that there was no difference in the performance of cfDNA analysis by the SNPs method between high and low risk pregnancies 7 . Therefore, extending the use of cfDNA testing to lower risk categories, with the main objective of increasing the detection rate for common trisomies, will depend upon local health policies and economic resources necessary to offer the test to larger proportions of the obstetric population. 
